Event
MarketKALSHIactive
MarketKALSHIactiveOther
What will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?
Part of: FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (in 2026)NoNo Price
99¢
|
VolTotal Volume
$0.00
|
Outcomes
2
Ends
Jan 8, 2027
in 6 monthsWhat will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?
No
99¢
|
Vol
$0.00
|
Outcomes
2
Yes0.9¢
No99.1¢
Price History
What will the FDA's decision be on bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences in 2026?
No historical data available
Price history will appear here when available
Resolution Info
Market Stats
Resolution Countdown
182 Days Left
January 08, 2027 • 3:00 PM
Last Updated
less than a minute ago